IVAX Awarded Large Antibiotic Contract From U.S. Government.
MIAMI--(BUSINESS WIRE)--Oct. 26, 2001
IVAX Corporation (AMEX:IVX), (LSE:IVX.L) confirmed today that its subsidiary, IVAX Pharmaceuticals, Inc., was awarded a U.S. Government contract to supply more than 1.2 billion tablets of the company's brand equivalent doxacycline 100 mg tablets and capsules. Doxacycline is one of several antibiotics used to treat anthrax.
"Filling this order is a top priority for us at this time of special concern for our country. As a leading manufacturer of antibiotics, we will, of course, make our full resources available to serve the needs required for our common welfare," said Rafick G. Henein, Ph.D., president and chief executive officer of IVAX Pharmaceuticals, Inc.
IVAX also has an application pending with the FDA for its ciprofloxacin, the generic equivalent of Cipro(R), the antibiotic most commonly used to treat anthrax.
IVAX Corporation, headquartered in Miami, Florida, is engaged in the research, development, manufacturing, and marketing of branded and brand equivalent pharmaceuticals and veterinary and diagnostic products in the U.S. and international markets.
Copies of this and other news releases may be obtained free of charge from IVAX' web site at http://www.ivax.com.
|Printer friendly Cite/link Email Feedback|
|Date:||Oct 26, 2001|
|Previous Article:||Nexsi Systems' Nexsi 8000 Named Best of Show Award Winner for NetWorld+Interop 2001 Atlanta.|
|Next Article:||Corporate Profile for CyberU Inc., dated Oct. 26, 2001.|